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Background: Statins inhibit proliferative signalling in oesophageal adenocarcinoma (OAC) and their use
is associated with better survival in observational studies. The present study was undertaken to examine
the feasibility of assessing adjuvant statin therapy in patients with operable OAC in a phase III RCT.
Methods: For this multicentre, double-blind, parallel-group, randomized, placebo-controlled feasibility
trial, adults withOAC (including Siewert I–II lesions) who had undergone oesophagectomywere centrally
allocated (1 : 1) to simvastatin 40mg or matching placebo by block randomization, stratified by centre.
Participants, clinicians and investigators were blinded to treatment allocation. Patients received treatment
for up to 1 year. Feasibility outcomes were recruitment, retention, drug absorption, adherence, safety,
quality of life, generalizability and survival.
Results: A total of 120 patients were assessed for eligibility at four centres, of whom 32 (26⋅7 per cent)
were randomized, 16 in each group. Seven patients withdrew. Participants allocated to simvastatin had
lower low-density lipoprotein cholesterol levels by 3months (adjusted mean difference −0⋅83 (95 per
cent c.i.−1⋅4 to−0⋅22) mmol/l; P = 0⋅009). Median adherence to medication was greater than 90 per cent
between 3 and 12months’ follow-up. Adverse events were similar between the groups. Quality-of-life data
were complete for 98⋅3 per cent of questionnaire items. Cardiovascular disease, diabetes and aspirin use
were more prevalent in the non-randomized group, whereas tumour site, stage and grade were similar
between groups. Survival estimates were imprecise.
Conclusion: This RCT supports the conduct and informs the design considerations for a future phase
III trial of adjuvant statin therapy in patients with OAC. Registration number: ISRCTN98060456
(www.isrctn/com).
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Introduction
Oesophageal adenocarcinoma (OAC) is an aggressive
malignancy with a poor prognosis1. Approximately 40
per cent of patients with OAC are treated with curative
intent by oesophagectomy2, with or without periop-
erative chemotherapy or chemoradiotherapy3. Despite
these high-risk interventions2, the 5-year survival rate
is still only 30 per cent4, with mortality attributable
mainly to recurrent disease5. Currently, there are no
longer-term evidence-based interventions after curative
surgical resection to prevent cancer recurrence and reduce
mortality.
There is growing experimental and observational evi-
dence that statins (3-hydroxy-3-methylglutaryl coenzyme
A reductase inhibitors) could be effective agents in the
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adjuvant setting6. Preclinical studies7–10 have demon-
strated antiproliferative, proapoptotic and antimetastatic
effects of statins in OAC. Gain-of-function mutations in
p53, the most commonly mutated gene in OAC11, have
been shown to upregulate transcription of mevalonate
pathway enzymes that sustain malignant proliferation12,13,
suggesting that this pathway may be a therapeutic target.
A recent systematic review14 of observational studies,
which included 95 cohorts with over a million patients
with cancer at numerous primary sites, demonstrated that
statin use after diagnosis was associated with significant
reductions in all-cause mortality (pooled hazard ratio (HR)
0⋅65, 95 per cent c.i. 0⋅60 to 0⋅72). Large independent
population-based cohort studies15–17 of patients with
OAC demonstrated that postdiagnostic statin use was
associated with significant reductions in all-cause and
oesophageal cancer-specific mortality. Importantly, the
association remains robust when accounting for cancer
stage, immortal-time bias and reverse-causation bias.
Malignant recurrence of OAC occurs despite care-
ful exclusion of overt disseminated disease at diagnosis
with preoperative staging modalities, implying the pres-
ence of subclinical micrometastatic cancer at the time
of oesophagectomy18. This group of patients has been
selected to investigate the adjuvant effects of statins as they
have minimal disease burden, yet substantial risk of recur-
rent disease19. Statins represent attractive adjuvant agents
to investigate in this setting as they are easily administered,
inexpensive and well tolerated, with an excellent safety
profile20–23. To establish the efficacy of statins as adjuvant
agents for OAC, a definitive phase III RCT is required.
However, uncertainties exist surrounding its feasibility and
conduct, particularly in the context of investigating a repur-
posed drug for an adjuvant indication. The aim of this study
was to determine the feasibility of a phase III RCT of adju-
vant statin therapy in patients following oesophagectomy
for OAC. The objectives were to determine: recruit-
ment and retention rates; generalizability of randomized
to non-randomized patients; drug absorption; treatment
adherence; a preliminary safety profile of simvastatin in this
patient population; completion rates of questionnaires and
exploratory comparisons of quality of life; and to estimate
treatment efficacy on disease-free and overall survival.
Methods
This feasibility study is reported in accordance with the
extension to the CONSORT 2010 statement for random-
ized pilot and feasibility trials24. The final study protocol
is available on request. Ethical approval was received
from National Research Ethics Service Committee South
Central, Oxford B (reference 14/SC/0247). The trial
received Medicines and Healthcare products Regulatory
Agency approval (reference 13630/005/001-0002). The
trial was registered with the European Clinical Trials
Database (EudraCT number 2014-001318-24) and the
ISRCTN registry (ISRCTN98060456).
Trial design and participants
The STATin therapy in the prevention of post-operative
Recurrence of Oesophageal adenoCarcinoma (STAT-
ROC) feasibility study is a multicentre, double-blind,
parallel-group, randomized, placebo-controlled trial of the
feasibility of assessing adjuvant statin therapy in a phase
III trial. An amendment to the protocol was approved to
ensure recruitment was sufficient to meet the minimum
target of 24 patients and improve study generalizability.
The study was allowed to expand from one to four sites,
and to extend recruitment from 31 October 2015 to 31
July 2016. Given that the recruitment period was extended
and the date for the end of the trial fixed (31 October
2016), follow-up was truncated for participants recruited
after 1 November 2015, which enabled at least 3months’
follow-up to determine drug absorption.
Adults with OAC (including adenocarcinoma of the
gastro-oesophageal junction, Siewert I–II lesions) due to
undergo curative resection were eligible. Patients were
excluded if they were already prescribed a statin or had a
contraindication to statin therapy. The eligibility criteria
are listed in full in Table S1 (supporting information).
Randomization and masking
Patients were assigned randomly to receive simvastatin
40mg or matched placebo in a 1 : 1 ratio. A computer-
generated randomization code (generated by Ipswich
Pharmacy Manufacturing Unit) was used to randomize
participants in blocks of four to six, stratified by site. The
randomization code stipulated the treatment allocation
according to a sequentially ordered four-digit subject
number. Identical sealed medication bottles were labelled
individually with corresponding subject numbers to pre-
serve allocation concealment. Participants were allocated
a subject number sequentially in the order they passed the
baseline assessment. An interactive web response system,
with password access limited to registered investigators,
allocated the subject numbers serially to recruited patients.
To preserve blinding, Ipswich Pharmacy Manufacturing
Unit produced identical active and placebo capsules.
Blood samples to measure low-density lipoprotein (LDL)
cholesterol were frozen and analysed after completion
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of the trial. Participants, their healthcare providers, data
collectors and outcome adjudicators were all blinded to
treatment allocation.
Procedures
Participants were identified at local upper gastrointestinal
cancermultidisciplinary teammeetings at each site. During
the recruitment period, a retrospective pseudoanonymous
review of all patients with OAC due to undergo curative
surgery (regardless of any exclusion criteria present) was
conducted. This generated a reference population against
which generalizability was assessed for the randomized
study population.
Potentially eligible patients were approached to consider
participation in the preoperative period during an outpa-
tient clinic appointment with their surgeon or oncologist.
They were issued an invitation letter and a participant
information sheet. A member of the research team saw
them at a screening visit before surgery, which usually
coincided with the day of their preoperative assessment.
During this visit, participants were screened to determine
eligibility, informed written consent was obtained, clin-
ical data were collected, blood was taken for tests for
safety (thyroid function tests, liver function tests (LFTs),
creatine kinase and creatinine estimation) and research
(LDL cholesterol)5, quality-of-life questionnaires (Euro-
pean Organisation for Research and Treatment of Cancer
(EORTC) QLQ-C30 and disease-specific oesophagogas-
tric QLQ-OG25 module questionnaires) were completed,
and feasibility study acceptance/declined questionnaires (as
appropriate) were completed. The research team wrote to
the patient’s general practitioner to confirm whether they
were due to be prescribed a statin.
Randomization took place for consenting participants
who satisfied the screening and eligibility assessments, and
who were due to be discharged after surgery. Participants
were prescribed trial medication once-daily to start from
the date of discharge.
Participants were followed up at 3, 6, 9 and 12months
after discharge. Follow-up assessments were scheduled to
coincide with hospital appointments as part of the partic-
ipant’s usual care. Follow-up visits included: confirmation
of any clinical contraindication to receiving trial medica-
tion; assessment of adverse events; drug safety assessments
(LFTs at 3 and 12months, and creatine kinase estimation if
muscle symptoms developed and the trial medication was
considered likely to be causal); quality-of-life question-
naires (as above); pill counts; blood tests for non-fasting
LDL cholesterol levels; medical notes review to deter-
mine disease outcomes, including cancer recurrence;
physical examination for evidence of recurrence if not
already diagnosed; and dispensing of trial drugs at 3, 6
and 9months from discharge after surgery. Participants
received trial medication for up to 1 year.
The trial steering and safety committees were consulted
every 6months for the duration of the trial.
Statistical analysis
A statistical analysis plan was finalized and approved by
the trial steering committee before blinding was broken
and analysis undertaken. The analyst was blind to group
allocation until analysis was complete. All eight outcomes
were viewed with equal primacy.
Recruitment
Recruitment was defined as the randomization of a trial
participant. Three aspects of recruitment were calculated:
the proportion of participants randomized from all those
who were assessed for eligibility (the denominator was
those with OAC due to have surgery); the proportion of
participants randomized from those who met all eligibility
criteria (except for whether or not they were willing to
consent); and the number of participants randomized per
month per centre.
Retention
Retention was defined as the date of withdrawal, which
included both complete withdrawal from the trial and with-
drawal of treatment but still undergoing active follow-up,
censored for recurrence or death. Kaplan–Meier survival
curves were plotted for the randomized population and by
treatment group. Differences between groups were deter-
mined with the log rank test.
Absorption
The primary outcome was change in non-fasting LDL
cholesterol at 3months after discharge, adjusted for LDL
cholesterol measured at screening in the intention-to-treat
(ITT) population. Adjusted and unadjusted mean differ-
ences in LDL cholesterol, measured between treatment
groups for 3–12months, were tabulated. Unadjusted com-
parisons were made using Student’s t-test, and adjusted
comparisons were conducted using analysis of co-variance
(ANCOVA). Sensitivity analyses using the method above
were repeated for the per-protocol population, defined for
this outcome as participants who adhered to least 80 per
cent of dispensed medications in the preceding 3months.
Generalizability
Demographic and clinical characteristics were compared
between randomized and non-randomized patients
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assessed for eligibility (who otherwise met the inclu-
sion criteria). Categorical data were compared using the
χ2 test or Fisher’s exact test as appropriate, and continuous
data using the two-sample t test or Mann–Whitney U test
as dictated by the distribution.
Adherence
Adherence was defined as the proportion of medication
consumed in the 3months preceding the research visit
(determined using pill counts as the actual number con-
sumed divided by the expected number consumed (days
elapsed between previous dispensation and subsequent
visit)). Adequate adherence was defined as administration
of at least 80 per cent of trial medication in this 3-month
period. Estimates for adherence exceeding 105 per cent for
the preceding 3months were considered implausible and
ignored (as were estimates for subsequent visits that were
reliant on these).
Safety
All reported adverse events were summarized accord-
ing to treatment received and tabulated with frequencies
(for the number of individuals with 1 or more adverse
events) according to category of adverse event and worst
grade experienced using Common Terminology Criteria
for Adverse Events v4.025. Safety analyses were restricted to
the trial population that successfully administered at least
one dose of trial medication. To address a protocol viola-
tion, whereby a patient allocated to placebo was dispensed
simvastatin in error at 6months, their safety data were con-
tributed to both groups (the placebo group until the viola-
tion, and the simvastatin group thereafter).
Quality of life
Compliance for completing quality-of-life questionnaire
items was tabulated for each study visit. Items on both
the EORTC QLQ-C30 and QLQ-OG25 were scored
and scaled, and missing values imputed in line with the
EORTC manual26. Differences in mean scores between
groups were adjusted for values observed at screening using
ANCOVA.
Exploratory survival comparisons
Overall survival was defined as time elapsed from discharge
from hospital to death from any cause. Disease-free sur-
vival was defined as the time elapsed from discharge to
the first time point at which recurrence or death occurred.
Kaplan–Meier survival curves with Cox proportional haz-
ards modelling compared treatment groups. All analyses
were performedwith STATA®version 13 (StataCorp, Col-
lege Station, Texas, USA).
Sample size
A sample size of 24was theminimum recruitment target for
the trial (gains in the precision of the mean difference for
outcomes measured on a continuous scale for participants
randomized in a 1 : 1 ratio are small above this number)
and was expected to satisfy assessment of feasibility out-
comes measured on a continuous scale27. A sample of 22
participants (11 per arm) had 80 per cent power at the 5
per cent level to detect a difference of 1mmol/l in LDL
cholesterol concentration, assuming a standard deviation
of 0⋅828.
Results
Between 21 October 2014 and 22 July 2016, 120 patients
with OAC who were due to undergo potentially cura-
tive surgery in four UK oesophagogastric centres (Nor-
wich, Chelmsford, Nottingham and Middlesbrough) were
assessed for eligibility (Fig. 1). In total 88 were excluded, of
whom 54 were ineligible as they were current statin users.
Of the 120 patients assessed for eligibility, 32 (26⋅7 (95 per
cent c.i. 19⋅0 to 35⋅5) per cent) were randomized equally to
simvastatin or placebo. The proportion of participants ran-
domized from those who met all eligibility criteria (except
whether or not they were willing to consent) was 59 (45⋅0
to 72⋅4) per cent (32 of 54). Of the three sites that random-
ized patients, the recruitment rates (permonth) in descend-
ing order were 1⋅31 (95 per cent c.i. 0⋅49 to 2⋅79), 1⋅16
(0⋅73 to 1⋅76) and 0⋅54 (0⋅18 to 1⋅24), and the cumulative
recruitment rate (per month) for these sites was 3⋅01 (2⋅59
to 3⋅48).
Baseline characteristics
Participant characteristics were generally well balanced
between treatment groups (Table 1). Mean(s.d.) age was
62⋅7(12⋅3) years in the placebo group and 66⋅6(8⋅7) years in
the simvastatin group. Thirteen participants in the placebo
group and 12 in the simvastatin group were men. Fif-
teen patients in each treatment group received neoad-
juvant chemotherapy. The majority of patients in both
groups received trial medication on the day they were
randomized.
Retention
Retention did not differ between treatment groups
(P = 0⋅630, log rank test). In total, seven patients with-
drew from the trial: four reported difficulty swallowing
the trial medication, one withdrew consent, one was pre-
scribed a non-trial statin during follow-up by their general
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Fig. 1 Trial profile
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 Inoperable n=5
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 Not approached before surgery n=2
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 Recruitment complete n=3
Screening and 3-month LDL measurement n=12
Adherence at 3 months n=13
Safety analyses n=14
QOL assessment at 3 months n=14
ITT analyses for survival n=16
Allocated to placebo n=16
Received intervention n=13
 Withdrew consent n=1
 Trial medication lost n=1
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Allocated to simvastatin n=16
Received intervention n=16
Randomized
n=32
Discontinued intervention n=3
 Difficulty swallowing n=2
 Adverse event n=1
Discontinued intervention n=3
 Difficulty swallowing n=2
 GP prescribed a statin n=1
Screening and 3-month LDL measurement n=14
Adherence at 3 months n=14
Safety analyses n=16
QOL assessment at 3 months n=15
ITT analyses for survival n=16
Completed 3-month visit n=14
 Final visit truncated at 3 months n=2
 Truncated follow-up between 3 and 6 months n=0
Completed 6-month visit n=12
 Final visit truncated at 6 months n=1
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Completed 9-month visit n=8
 Final visit truncated at 9 months n=4
 Truncated follow-up between 9 and 12 months n=0
Completed 12-month visit n=4
Lost to follow-up n=0
Died n=1
 < 3 months n=1
Completed 3-month visit n=16
 Final visit truncated at 3 months n=0
 Truncated follow-up between 3 and 6 months n=1
Completed 6-month visit n=14
 Final visit truncated at 6-months n=1
 Truncated follow-up between 6 and 9 months n=0
Completed 9-month visit n=12
 Final visit truncated at 9 months n=4
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*In addition to being current statin users, three patients also met the other exclusion criteria listed. GP, general practitioner; LDL, low-density lipoprotein;
QOL, quality of life; ITT, intention to treat.
practitioner, and one developed transaminitis (Fig. 2a,b;
Table S2, supporting information). Aside from two with-
drawals between 3 and 6months, all other withdrawals
happened within 27 days of randomization. The overall
annual rate of withdrawal per person was 0⋅36 (95 per cent
c.i. 0⋅17 to 0⋅76). The highest rate was observed in the
first 3months (0⋅74, 0⋅31 to 1⋅77), before falling between
3 and 6months to 0⋅36 (0⋅09 to 1⋅46); thereafter there
were no further losses to follow-up (Table S3, supporting
information).
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Table 1 Baseline characteristics of randomized participants
Placebo
(n = 16)
Simvastatin
(n = 16)
Age at randomization (years)* 62⋅7(12⋅3) 66⋅6(8⋅7)
Time from diagnosis to randomiza-
tion (days)*
153⋅4(31⋅8) 155(40⋅8)
Time from randomization to receiv-
ing trial medication (days)
0 (0–1) 0 (0–0)
Sex ratio (M : F) 13 : 3 12 : 4
Smoking status
Current smoker 1 2
Ex-smoker 10 11
Never smoked 5 3
BMI (kg/m2)* 26⋅2(4⋅1) 26⋅6(4⋅7)
Co-morbid condition
Cardiovascular 0 1
Diabetes 0 0
Charlson co-morbidity index†
0 15 14
1 1 2
Perioperative aspirin use 0 0
ECOG performance status
0 16 13
1 0 2
2 0 1
LDL cholesterol (mmol/l)* 3⋅51(0⋅89) 3⋅73(0⋅92)
Tumour site
Oesophagus 7 5
Siewert I 2 4
Siewert II 7 7
Tumour grade
Gx 2 1
G1 0 0
G2 5 8
G3 9 6
G4 0 1
cT category
2 0 1
3 16 12
4 0 1
4a 0 2
cN category
0 2 5
1 9 6
2 4 4
3 1 1
Neoadjuvant chemotherapy
Yes 15 15
No 1 1
Preoperative radiotherapy
Yes 0 1
No 16 15
Table 1 Continued
Placebo
(n = 16)
Simvastatin
(n = 16)
Oesophagectomy
Open 4 2
Hybrid 9 10
Minimally invasive 3 4
Lymph node yield 26 (19–42) 22 (25–35)
Positive lymph nodes 1⋅5 (0–4⋅5) 1 (0–3)
Vascular invasion
Yes 9 5
No 7 11
Margin status
R1 4 3
R0 12 13
Postoperative length of stay (days) 10 (6–13) 9 (6–12)
Any postoperative in-hospital
complication
7 6
Global quality-of-life score*‡ 68(20) 73(10)
Values in parentheses are interquartile ranges unless indicated otherwise;
*values are mean(s.d.). †Modified Charlson co-morbidity index (excludes
solid tumours). ‡A high score suggests a high level of functioning. ECOG,
Eastern Cooperative Oncology Group; LDL, low-density lipoprotein.
Generalizability
No significant differences were found between
non-randomized and randomized patient populations
for age at diagnosis, sex, smoking status, BMI, tumour site,
tumour grade, clinical stage or preoperative radiotherapy
(Table S4, supporting information). As expected, there
were significant differences between treatment groups
for cardiovascular disease, diabetes and aspirin use, which
were all more prevalent in the non-randomized group.
Furthermore, a significantly higher proportion in the
randomized group had better performance status, and
underwent neoadjuvant chemotherapy.
Absorption
Compared with placebo users, patients allocated to sim-
vastatin had a significantly lower mean difference in LDL
cholesterol by 3months, adjusted for values at screening
(0⋅83 (95 per cent c.i. −1⋅40 to 0⋅22) mmol/l; P = 0⋅009)
(Table 2 and Fig. 2c,d), equivalent to a 27⋅6 per cent pro-
portionate reduction. Similar reductions in LDL choles-
terol persisted for the maximum duration of follow-up
(12months).
Adherence
Overall adherence was lowest in the first 3months of treat-
ment (median adherence 83 (i.q.r. 45–98) per cent) before
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Fig. 2 Kaplan–Meier analysis of time to withdrawal, low-density lipoprotein cholesterol during follow-up, and adherence to trial
medication
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a,b Time to withdrawal overall (a) and according to treatment allocation (b). c,d Mean plasma low-density lipoprotein (LDL) cholesterol levels during
follow-up according to treatment allocation for intention-to-treat (c) and per-protocol (d) populations. Half error bars span from the mean to the upper
or lower limit of the 95 per cent confidence interval. e,fMedian percentage adherence to trial medication overall (e) and according to treatment allocation
(f), calculated at each trial visit for the preceding 3months. Half error bars span from the median to the upper or lower limit of the interquartile range.
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Table 2 Comparison of non-fasting plasma low-density lipoprotein cholesterol by treatment group
Placebo Simvastatin
n LDL (mmol/l)* n LDL (mmol/l)*
Unadjusted mean
difference P‡
Adjusted mean
difference† P‡
Intention-to-treat
3-month visit 13 3⋅00(0⋅54) 15 2⋅20(0⋅85) −0⋅80 (−1⋅36 to −0⋅24) 0⋅007 –0⋅83 (–1⋅40 to –0⋅22) 0⋅009
6-month visit 10 3⋅09(0⋅63) 14 2⋅14(1⋅01) −0⋅95 (−1⋅71 to −0⋅20) 0⋅016 –1⋅23 (–1⋅85 to –0⋅40) 0⋅004
9-month visit 8 2⋅89(0⋅61) 12 2⋅17(0⋅74) −0⋅72 (−1⋅39 to −0⋅05) 0⋅036 –0⋅79 (–1⋅47 to –0⋅11) 0⋅025
12-month visit 4 3⋅00(0⋅28) 6 2⋅07(0⋅47) −0⋅93 (−1⋅54 to −0⋅33) 0⋅008 –0⋅99 (–1⋅58 to –0⋅40) 0⋅007
Per-protocol
3-month visit 7 3⋅00(0⋅60) 9 2⋅46(0⋅96) −0⋅53 (–1⋅42 to 0⋅36) 0⋅224 –0⋅49 (–1⋅47 to 0⋅49) 0⋅300
6-month visit 8 3⋅09(0⋅66) 12 2⋅09(1⋅09) –1⋅00 (–1⋅91 to –0⋅09) 0⋅034 –1⋅16 (–2⋅01 to –0⋅32) 0⋅010
9-month visit 7 2⋅86(0⋅66) 12 2⋅17(0⋅74) –0⋅69 (–1⋅41 to 0⋅03) 0⋅058 –0⋅74 (–1⋅47 to –0⋅00) 0⋅049
12-month visit 3 3⋅07(0⋅31) 5 2⋅02(0⋅51) –1⋅05 (–1⋅85 to –0⋅24) 0⋅019 –1⋅16 (–1⋅96 to –0⋅35) 0⋅016
Values in parentheses are 95 per cent confidence intervals unless indicated otherwise; *values are mean(s.d.). Analysis by ANCOVA. †Adjusted for screening
values. A negative difference implies that patients taking simvastatin have a lower low-density lipoprotein (LDL) cholesterol level than those on placebo.
‡Student’s t-test and ¶ calculated by ANCOVA.
Table 3 Adherence to trial medication during follow-up
Placebo Simvastatin Overall
3-month visit
No. of patients 13 14 27
No. with adherence ≥80% 6 8 14
Adherence (%)* 77 (38–98) 85 (63–99) 83 (45–98)
6-month visit
No. of patients 10 8 18
No. with adherence ≥80% 8 6 14
Adherence (%)* 94 (90–100) 92 (67–99) 94 (83–100)
9-month visit
No. of patients 5 5 10
No. with adherence ≥80% 5 5 10
Adherence (%)* 97 (96–99) 100 (99–100) 99 (96–100)
12-month visit
No. of patients 3 5 8
No. with adherence ≥80% 2 4 6
Adherence (%)* 92 (78–98) 96 (85–100) 94 (82–99)
*Median (i.q.r.) percentage adherence to at least 80 per cent of trial med-
ication in the preceding 3months. No implausible values for adherence
(greater than 105 per cent) were observed at 3months. Values from three
patients were ignored at 6months (and thereafter), values fromfive patients
were ignored at 9months (and thereafter) and none were ignored at
12months.
improving at subsequent visits at 6months (median 94
(83–100) per cent), 9months (median 99 (96–100) per
cent) and 12months (median 94 (82–99) per cent) (Table 3
and Fig. 2e,f ). Adherence was similar between the two
groups.
Safety
There were 108 individual adverse events affecting 27
participants (Table 4; Table S5, supporting information).
In total 20 (18⋅5 per cent) were serious adverse events
(13 in the placebo and 7 in the simvastatin arm). There
were no suspected serious adverse reactions or suspected
unexpected serious adverse reactions. Before unblind-
ing, of all individual adverse events 94 were assessed as
unrelated to the trial medication, 12 were assessed as
unlikely to be related, and two were assessed to be possibly
related (grade 3 transaminitis, which was subsequently
downgraded to grade 2 in the same patient, who had
been allocated placebo). There were similar proportions
and severity grading of individual adverse events in each
group.
Quality of life
Overall completion of questionnaire items was 98⋅3 per
cent (6278 of 6385); thus, 107 values (1⋅7 per cent) were
imputed. Overall, adjusted differences between groups for
QLQ-C30 function scores and QLQ-OG25 symptoms
scales were small (Table S6, Figs S1 and S2, supporting
information).
Survival
During 22⋅9 person-years of follow-up, four participants
developed distal recurrent disease (2 in each group); of
these, three patients died (1 in the placebo and 2 in the
simvastatin group). Median overall and disease-free sur-
vival were not reached. There was no significant dif-
ference between groups for overall (HR 1⋅56, 95 per
cent c.i. 0⋅14 to 17⋅28; P = 0⋅716) or disease-free (HR
0⋅78, 0⋅11 to 5⋅61; P = 0⋅807) survival (Fig. S3, supporting
information).
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Table 4 Adverse events by treatment allocation
No. with at least 1 adverse event
CTCAE system
organ class Placebo Simvastatin
Blood 1 0
Ear 1 1
Gastrointestinal 11 9
General disorders 3 5
Infections 3 4
Investigations 3 2
Transaminitis 1 0
Metabolism and nutrition 0 1
Musculoskeletal 1 5
Myalgia 1 2
Neoplasms 1 0
Nervous system 2 3
Psychiatric 2 2
Renal and urinary 1 1
Respiratory 4 2
Skin 1 1
Vascular 2 1
Any 13 14
CTCAE, Common Terminology Criteria for Adverse Events.
Discussion
This multicentre, double-blind, parallel-group,
placebo-controlled trial has reported outcomes for 32
participants randomized to simvastatin 40mg or placebo
to determine the feasibility of adjuvant statin therapy in
patients with operable OAC in a future phase III trial.
The study has demonstrated that patients were willing
to enter the trial, and their consultants were willing to
recruit them. The proportion of patients randomized from
those assessed for eligibility and from those meeting inclu-
sion criteria was favourable, and informs the recruitment
of centres for a future RCT. Assuming 4 years of recruit-
ment, with 3 years’ follow-up after the last randomization,
an absolute mortality difference of 7 per cent by 3 years
(HR 0⋅80), 80 per cent power at the 5 per cent significance
level, and accounting for attrition and contamination of the
exposure, would require 976 patients. Assuming an aver-
age recruitment rate of 26⋅7 per cent (derived from this
feasibility study, which accounts for prevalent statin use)
of patients undergoing oesophagectomy for OAC, with
participation of at least 25 UK oesophagogastric cancer
centres, complete recruitment within 4 years is feasible.
Rates of withdrawal were highest in the first 3months of
follow-up, contributed to mainly by difficulties in swallow-
ing trial medication. Participants who continued to partic-
ipate from 1month after discharge were more likely to be
retained. These data provide strong impetus to manufac-
ture smaller, bespoke, more easily swallowed (and ideally
suitable for crushing) study medication for a future trial.
The early dropouts observed provide justification for the
implementation of a run-in period before randomization
in a future trial. As a result of these planned adaptations, it
is expected the withdrawal rates in a future phase III RCT
would be lower than that observed in this feasibility study.
Comparisons between randomized and non-randomized
groups provide strong evidence for systematic differences
between groups for the prevalence of cardiovascular dis-
ease, diabetes and aspirin use. This is expected as the trial
excluded users of statins, indicated in patients with these
conditions, often with shared indications for aspirin use.
A significant reduction in non-fasting LDL cholesterol
between randomized treatment groups at 3months in
the ITT population provides good evidence to infer that
statins are absorbed sufficiently to produce a pharmacody-
namic effect. This is important to demonstrate, as patients
are vagotomized during oesophagectomy, affecting gas-
trointestinal transit, which could hypothetically impair
drug absorption. Reductions in LDL cholesterol were
consistent with those observed in the Medical Research
Council–British Heart Foundation Heart Protection
Study28 (mean(s.e.) difference overall −1⋅0(0⋅02) mmol/l).
Longer-term statin absorption over the course of the trial
was also confirmed.
Adherence, determined using pill counts, was poorest in
the first 3months, but was greatly improved thereafter. At
least three-quarters of the cohort adhered to at least 80 per
cent of the trial medication from 3months. Adherence data
are applicable only to the first year of treatment. Adherence
was similar between treatment groups. Furthermore, inter-
pretation should also consider the known limitations of pill
counts, as they can overestimate adherence29. Neverthe-
less, the data from pill counts taken together with the com-
parison of LDL cholesterol between groups would suggest
that adherence was sufficient to support a future trial.
There was no evidence to suggest an adverse safety pro-
file in this patient population with statin use, either in terms
of the absolute numbers of adverse events or in terms of
their severity. There is no plausible reason to suggest the
adverse event profile should be different in this cohort, and
there are no known interactions with current chemother-
apy regimens and statins, and no evidence of excess of harm
when co-administered in the trial setting30,31. Completion
of both the QLQ-C30 and QLQ-OG25 questionnaires
was high overall (98⋅3 per cent) and at each follow-up visit,
suggesting the feasibility of assessing quality of life in a
future phase III RCT. Adjusted differences between groups
were small and not clinically significant (a value of 8 points
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difference has previously been deemed to be of clinical
importance)32. In line with guidance on the conduct of fea-
sibility studies, this study was not powered to test efficacy.
Estimates of overall and disease-free survival were impre-
cise with contradictory point estimates, precluding their
use in determining an effect size for a future trial.
This is the first RCT to determine the feasibility of
assessing postoperative statin therapy in patients with OAC
in a future phase III study. The effect of simvastatin
80mg has been assessed previously in patients undergo-
ing oesophagectomy in a single-centre RCT33. The aim of
that study was to determine the effect of perioperative sim-
vastatin 80mg (versus placebo) on pulmonary dead space
to determine the potential of high-dose statin therapy in
preventing acute lung injury. Similar to the present study,
the prevalence of statin use was high (31 of 63 patients
excluded (49 per cent) were prevalent statin users). Pub-
lished trials (3 of which were phase III and have been
summarized previously34) have assessed the effect of allo-
cation to statins on mortality outcomes in patients with
solid tumours30,31,35–41 including gastro-oesophageal30,31,
colorectal35, pancreatic36, hepatocellular37 and lung38,40,41.
The largest RCT to date, LUNGSTAR40, of 846 patients
with small-cell lung cancer, demonstrated no improvement
with pravastatin 40mg on overall survival (HR 1⋅01, 95
per cent c.i. 0⋅88 to 1⋅16). In 244 patients with metastatic
gastro-oesophageal junction or gastric adenocarcinoma,
simvastatin 40mg in addition to palliative chemotherapy
did not improve overall survival. However, it is difficult to
draw comparison with previous trials as they all recruited
patients with known metastatic disease, and the potential
benefits of statins are likely greatest in the adjuvant setting.
Of relevance, there was no evidence to suggest a clinically
significant increase in toxicity with statin allocation.
Add-Aspirin, a phase III RCT of adjuvant aspirin ther-
apy in four disease cohorts (gastro-oesophageal, breast,
prostate and colorectal cancer) is currently recruiting42.
Patients with adenocarcinoma, adenosquamous carci-
noma or squamous cell carcinoma of the oesophagus,
gastro-oesophageal junction or stomach are eligible for
inclusion in the gastro-oesophageal cohort, and hence
the inclusion criteria are broader than for STAT-ROC.
Add-Aspirin demonstrates the appetite of funders, investi-
gators, clinicians and patients for investigating repurposed
medication as adjuvant cancer therapy. One patient was
successfully co-enrolled into both trials.
This study has a number of strengths. It was possible to
assess the ‘real-world’ feasibility of a future phase III RCT
in the setting of a multicentre trial, to provide valid esti-
mates of feasibility parameters. The trial has established
the prevalence of statin use in the target trial population,
a notable risk to study feasibility. These data are infor-
mative in assessing trial feasibility to enable planning of
expected recruitment. This trial has provided valuable
information for devising strategies to improve retention
in a future trial, particularly regarding the manufacture of
smaller trial medication that can be easily swallowed and
ideally crushed. It was also possible to establish that trial
procedures were acceptable at different sites to clinicians,
research staff and patients.
This study has a number of limitations. Despite use of
the smallest available simvastatin tablets and smallest pos-
sible gelatine capsules to preserve blinding, the trial med-
ications were relatively large (measuring 23⋅3× 8⋅53mm).
Of patients who withdrew, difficulty swallowing the cap-
sules was the most commonly cited reason. Although this
trial estimated retention, this is unlikely to be applicable to
a future trial where use of smaller trial medication would
be justified and viable. This makes estimates of retention
less certain, necessitating further assumptions for a future
trial. Retention in a future trial would be much improved
with use of an open-label run-in period and smaller trial
medication. Feasibility estimates support the conduct and
inform the design considerations for a future trial.
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